Palonosetron hydrochloride LA is under clinical development by LP Pharmaceutical (Xiamen) and currently in Phase III for Chemotherapy Induced Nausea and Vomiting. According to GlobalData, Phase III drugs for Chemotherapy Induced Nausea and Vomiting have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Palonosetron hydrochloride LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Palonosetron hydrochloride LA overview
Palonosetron hydrochloride is under development for the treatment of chemotherapy induced nausea and vomiting. The drug candidate targets 5HT3 receptor. It is a long acting preparation, administered through intravenous route as solution and buccal route as film.
LP Pharmaceutical (Xiamen) overview
LP Pharmaceutical (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.
For a complete picture of Palonosetron hydrochloride LA’s drug-specific PTSR and LoA scores, buy the report here.